Sign In
|
Register
|
About Los Altos
|
Contact Us
Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast
|
Traffic
Los Altos News
Local News
Bay Area News
Business
Technology
Real Estate
Sports
High School Sports
Los Altos Gas Prices
Ski And Snow Reports
Financial Markets
Bagels
Bakery
Barbecue
Coffee Houses
Continental
Deli
Fast Food
French
Ice Cream / Frozen Yogurt
Italian
Mexican
Pizza
Steaks, Chops
Sushi
Vietnamese
Wine
Museums
Family Fun
Arts & Culture
Parks
Annual Events
Accommodations
Hotel and Motel Management
Hotels & Resorts
Apartments
Art & Culture
Galleries & Dealers
Museums
Associations, Foundations and Organizations
Business & Professional Clubs
Civic, Social and Fraternal
Non-Profits
Professional & Trade Associations
Attractions & Entertainment
Amusement & Water Parks
Bowling, Billiards & Video Games
General Attractions
Golfing
Horseback Riding
Movie Theatres
Theatre
Automotive
Auto Rental
Dealers - New
Dealers - Used
Mobile Home Dealers
Motorcycles
Parts & Supplies
Radio & Alarm Systems
Repair & Service
Tires
Towing
Beauty & Fitness
Barbers
Beauty Salons
Cosmetics
Dance Clubs & Studios
Health Clubs & Gyms
Manicures
Nutrition
Skin Treatment
Yoga
Business & Professional Services
Appraisers
Building Maintenance & Janitorial
Business & Labor Organizations
Computer & Audio Visual Services
Consultants
Courier, Delivery & Messenger Service
Credit Check & Collection Agencies
Data Processing Service
Employment Services, Placement & Agencies
Engineer and Architect Services
Equipment & Supplies, Commercial & Industrial
Graphic Design & Art
Human Resource Services
Internet Services
Marketing & Advertising Services
Media Services
Notary Services
Photography
Printing & Publishing
Public Relations & Publicity
Security & Investigative Services
Shipping, Packaging & Postal Services
Signs & Banners
Staffing & Support Services
Translators & Interpreters
Contractors
Architects
Building Contractors & Consultants
Drywall, Plastering & Insulation
Electric
General Contractors
Heating, Cooling & AC
Landscaping
Painting & Wallcovering
Plumbing
Special Trade Contractors
Domestic Services
Child Care Services
Housecleaning
Pet Sitting and Day Care
Education
Colleges & Universities
Cont. Education
Elementary Schools
High Schools
Libraries
Preschools & Childcare
Private & Parochial
Public
Tutoring
Employment
Employment Agencies
Find or Post a Job
Temporary Help & Employment Contractors
Financial Services
Accountants & Tax
Banks & Credit Unions
Bookkeeping
Financial Brokers and Dealers
Financial Consultants
Financial Planning and Services
Investments
Loans
Mortgage Lenders
Golf
Government
Post Offices
State Government
Hair Salons
Health and Medicine
Alternative Medicine / Acupuncture
Chiropractors
Counseling
Dentistry
Dermatologists
Drug Stores & Pharmacies
Eye Care
Health Care Professionals
Home Health Care
Hospitals & Clinics
Medical Doctors
Medical Equipment & Supplies
Nutrition
Physical Therapist
Physicians & Surgeons
Social Services
Specialists - Health Care Professionals
Home & Garden
Appliances
Bed & Bath
Building Materials & Hardware
Cleaning Supplies & Services
Contractors
Domestic Services
Doors, Windows & Drapery
Floor Coverings
Furniture
Handyman
Home Improvement Centers
Interior Design & Decorating
Kitchen
Lamps & Lighting
Lawn & Garden
Locksmiths
Lumber
Nurseries & Garden Centers
Painting & Wallcoverings
Pest Control
Plumbing
Pools, Spas & Saunas
Safety & Security
Sewage & Septic Systems
Sprinklers
Insurance
Agents & Brokers
Health
Laser Hair Removal
Legal
Attorneys
Legal Services
Manufacturing & Industrial
Agriculture
Audio & Visual
Building Materials
Computers, Electronics & Telecommunications
Electronic Equipment
Food & Beverage
Industrial Supplies & Services
Machine Shops
Textiles & Apparel
Media
Radio Stations
Television Stations
Meeting & Event Planning
Event Facilities
Exhibit Designers
Meeting Planners
Party Rentals & Entertainment
Miscellaneous
Nightlife
Live Music
Personal Service
Child Care
Dry Cleaning and Laundry
Shoe Repair
Tailors and Alterations
Pets
Pet Grooming
Pet Supplies & Food - Retail
Veterinary Hospitals
Plastic Surgery
Aesthetic Surgeon
Plastic Surgeon
Real Estate
Appraisers
Assisted Living & Elder Care Service
Commercial
Developers
Property Management
Real Estate Agents and Brokers
Residential
Schools
Title Companies
Religion
Relocation
Storage
Restaurants
Bagels
Bakery
Barbecue
Coffee Houses
Continental
Deli
Fast Food
French
Ice Cream / Frozen Yogurt
Italian
Mexican
Pizza
Steaks, Chops
Sushi
Vietnamese
Wine
Shopping
Accessories
Antiques
Books
Cellular & Wireless
Children's and Infants Clothing
Clothing
Computer and Computer Software
Department Stores
Electronics
Flowers
Furniture
Gas Stations
Gifts & Specialty Shops
Grocery Stores
Health Food Stores
Home Improvement
Jewelry
Men's Clothing Stores
Pharmacies
Resale Shops
Shoe Stores
Shopping Centers & Malls
Smoke Shops
Sporting Goods
Thrift Stores
Toy Stores
Videos
Women's Clothing Stores
Spas
Day Spas
Resort Spas
Sports & Recreation
Arenas and Venues
Associations & Clubs
Equestrian
Golf Equipment & Supplies
Instruction
Martial Arts
Recreation Facilities
Skateboarding
Technology
Communications
Computer Services & Consultants
Internet Advertising & Services
Semiconductor
Software
Travel & Transportation
Airlines & Airports
Auto Rentals
Bus Lines & Charters
Taxi, Limousine & Shuttle
Tours & Excursions
Travel Agencies
Weddings
Cakes & Caterers
Your Business Here
Classifieds
Cars
Forums
Coupons
News Archives
Contests
Jobs
Search Hotels in Los Altos
CHECK-IN:
CHECK-OUT:
ROOMS:
1
2
3
4
Find A Business
or
Browse Listings
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adaptimmune Ther ADR
(NQ:
ADAP
)
1.210
+0.040 (+3.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Adaptimmune Ther ADR
< Previous
1
2
Next >
Adaptimmune Reports Q2 2024 Financial and Business Updates
August 12, 2024
Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumorPatients can...
Via
Newsfile
Exposures
Product Safety
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
August 01, 2024
From
Adaptimmune Therapeutics plc
Via
Business Wire
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
June 03, 2024
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response...
Via
Newsfile
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
May 31, 2024
Via
AB Newswire
Exposures
Product Safety
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
May 30, 2024
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell...
Via
Newsfile
Adaptimmune Reports Q1 2024 Financial and Business Updates
May 15, 2024
Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date...
Via
Newsfile
Exposures
Product Safety
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
May 15, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
May 01, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
April 12, 2024
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader...
Via
Newsfile
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
March 27, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
March 06, 2024
U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date...
Via
Newsfile
Topics
Economy
Exposures
Product Safety
Supply Chain
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
February 27, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
February 21, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
January 31, 2024
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for...
Via
Newsfile
Exposures
Product Safety
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
January 04, 2024
Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be...
Via
Newsfile
Exposures
Product Safety
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
December 06, 2023
First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug AdministrationAfami-cel data demonstrate better...
Via
Newsfile
Exposures
Product Safety
Adaptimmune Receives Transfer of IND for Lete-cel Program
November 29, 2023
Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma...
Via
Newsfile
Adaptimmune Reports Third Quarter Financial Results and Business Update
November 08, 2023
Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission...
Via
Newsfile
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
November 08, 2023
Candidate is 10x more sensitive to target peptide than competitor candidatesEntry into the clinic in 2024Selection of approaches from next-gen...
Via
Newsfile
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
October 31, 2023
~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response...
Via
Newsfile
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
October 31, 2023
40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had...
Via
Newsfile
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
October 25, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in...
Via
Newsfile
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
October 23, 2023
35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across...
Via
Newsfile
Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
September 11, 2023
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces...
Via
Newsfile
Adaptimmune Reports Second Quarter Financial Results and Business Update
August 09, 2023
Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell...
Via
Newsfile
Exposures
Product Safety
Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
August 03, 2023
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader...
Via
Newsfile
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
June 01, 2023
First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023Compelling clinical...
Via
Newsfile
Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO
May 25, 2023
Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1...
Via
Newsfile
Adaptimmune Reports First Quarter Financial Results and Business Update
May 12, 2023
Completed submission of the clinical module (Part 2) of the afami-cel BLA; afami-cel is targeted to be the first marketed...
Via
Newsfile
Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023
April 28, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell...
Via
Newsfile
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
About Us
|
Contact Us
|
Privacy Policy
|
User Agreement
|
Advertise With Us
|
Site Map
Home
|
News
|
Travel
|
Restaurants
|
Nightlife
|
Things To Do
|
Shopping
|
Events
|
Directory
|
Real Estate
|
Blog
|
More
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.